The challenge of developmental therapeutics for adrenocortical carcinoma

Ricardo Costa*, Benedito A Carneiro Filho, Fabio Tavora, Sachin G. Pai, Jason B Kaplan, Young Kwang Chae, Sunandana Chandra, Peter Andreas Kopp, Francis Joseph Giles

*Corresponding author for this work

Research output: Contribution to journalReview article

12 Citations (Scopus)

Abstract

Adrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of only 0.7 new cases per million per year. Approximately 30-70% of the patients present with advanced disease with very poor prognosis and without effective therapeutic options. In the recent years, unprecedented progresses in cancer biology and genomics have fostered the development of numerous targeted therapies for various malignancies. Immunotherapy has also transformed the treatment landscape of malignancies such as melanoma, among others. However, these advances have not brought meaningful benefits for patients with ACC. Extensive genomic analyses of ACC have revealed numerous signal transduction pathway aberrations (e.g., insulin growth factor receptor and Wnt/β-catenin pathways) that play a central role in pathophysiology. These molecular alterations have been explored as potential therapeutic targets for drug development. This manuscript summarizes recent discoveries in ACC biology, reviews the results of early clinical studies with targeted therapies, and provides the rationale for emerging treatment strategies such as immunotherapy.

Original languageEnglish (US)
Pages (from-to)46734-46749
Number of pages16
JournalOncotarget
Volume7
Issue number29
DOIs
StatePublished - Jan 1 2016

Fingerprint

Adrenocortical Carcinoma
Immunotherapy
Therapeutics
Catenins
Neoplasms
Wnt Signaling Pathway
Growth Factor Receptors
Rare Diseases
Genomics
Melanoma
Signal Transduction
Insulin
Incidence
Pharmaceutical Preparations

Keywords

  • Adrenocortical carcinoma
  • IGF-1R
  • Targeted therapy
  • VEGFR
  • β-catenin

ASJC Scopus subject areas

  • Oncology

Cite this

Costa, R., Carneiro Filho, B. A., Tavora, F., Pai, S. G., Kaplan, J. B., Chae, Y. K., ... Giles, F. J. (2016). The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget, 7(29), 46734-46749. https://doi.org/10.18632/oncotarget.8774
Costa, Ricardo ; Carneiro Filho, Benedito A ; Tavora, Fabio ; Pai, Sachin G. ; Kaplan, Jason B ; Chae, Young Kwang ; Chandra, Sunandana ; Kopp, Peter Andreas ; Giles, Francis Joseph. / The challenge of developmental therapeutics for adrenocortical carcinoma. In: Oncotarget. 2016 ; Vol. 7, No. 29. pp. 46734-46749.
@article{41a0fae64e4d40569f61867fbe5e8caa,
title = "The challenge of developmental therapeutics for adrenocortical carcinoma",
abstract = "Adrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of only 0.7 new cases per million per year. Approximately 30-70{\%} of the patients present with advanced disease with very poor prognosis and without effective therapeutic options. In the recent years, unprecedented progresses in cancer biology and genomics have fostered the development of numerous targeted therapies for various malignancies. Immunotherapy has also transformed the treatment landscape of malignancies such as melanoma, among others. However, these advances have not brought meaningful benefits for patients with ACC. Extensive genomic analyses of ACC have revealed numerous signal transduction pathway aberrations (e.g., insulin growth factor receptor and Wnt/β-catenin pathways) that play a central role in pathophysiology. These molecular alterations have been explored as potential therapeutic targets for drug development. This manuscript summarizes recent discoveries in ACC biology, reviews the results of early clinical studies with targeted therapies, and provides the rationale for emerging treatment strategies such as immunotherapy.",
keywords = "Adrenocortical carcinoma, IGF-1R, Targeted therapy, VEGFR, β-catenin",
author = "Ricardo Costa and {Carneiro Filho}, {Benedito A} and Fabio Tavora and Pai, {Sachin G.} and Kaplan, {Jason B} and Chae, {Young Kwang} and Sunandana Chandra and Kopp, {Peter Andreas} and Giles, {Francis Joseph}",
year = "2016",
month = "1",
day = "1",
doi = "10.18632/oncotarget.8774",
language = "English (US)",
volume = "7",
pages = "46734--46749",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "29",

}

Costa, R, Carneiro Filho, BA, Tavora, F, Pai, SG, Kaplan, JB, Chae, YK, Chandra, S, Kopp, PA & Giles, FJ 2016, 'The challenge of developmental therapeutics for adrenocortical carcinoma', Oncotarget, vol. 7, no. 29, pp. 46734-46749. https://doi.org/10.18632/oncotarget.8774

The challenge of developmental therapeutics for adrenocortical carcinoma. / Costa, Ricardo; Carneiro Filho, Benedito A; Tavora, Fabio; Pai, Sachin G.; Kaplan, Jason B; Chae, Young Kwang; Chandra, Sunandana; Kopp, Peter Andreas; Giles, Francis Joseph.

In: Oncotarget, Vol. 7, No. 29, 01.01.2016, p. 46734-46749.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The challenge of developmental therapeutics for adrenocortical carcinoma

AU - Costa, Ricardo

AU - Carneiro Filho, Benedito A

AU - Tavora, Fabio

AU - Pai, Sachin G.

AU - Kaplan, Jason B

AU - Chae, Young Kwang

AU - Chandra, Sunandana

AU - Kopp, Peter Andreas

AU - Giles, Francis Joseph

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Adrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of only 0.7 new cases per million per year. Approximately 30-70% of the patients present with advanced disease with very poor prognosis and without effective therapeutic options. In the recent years, unprecedented progresses in cancer biology and genomics have fostered the development of numerous targeted therapies for various malignancies. Immunotherapy has also transformed the treatment landscape of malignancies such as melanoma, among others. However, these advances have not brought meaningful benefits for patients with ACC. Extensive genomic analyses of ACC have revealed numerous signal transduction pathway aberrations (e.g., insulin growth factor receptor and Wnt/β-catenin pathways) that play a central role in pathophysiology. These molecular alterations have been explored as potential therapeutic targets for drug development. This manuscript summarizes recent discoveries in ACC biology, reviews the results of early clinical studies with targeted therapies, and provides the rationale for emerging treatment strategies such as immunotherapy.

AB - Adrenocortical carcinoma (ACC) is a rare disease with an estimated incidence of only 0.7 new cases per million per year. Approximately 30-70% of the patients present with advanced disease with very poor prognosis and without effective therapeutic options. In the recent years, unprecedented progresses in cancer biology and genomics have fostered the development of numerous targeted therapies for various malignancies. Immunotherapy has also transformed the treatment landscape of malignancies such as melanoma, among others. However, these advances have not brought meaningful benefits for patients with ACC. Extensive genomic analyses of ACC have revealed numerous signal transduction pathway aberrations (e.g., insulin growth factor receptor and Wnt/β-catenin pathways) that play a central role in pathophysiology. These molecular alterations have been explored as potential therapeutic targets for drug development. This manuscript summarizes recent discoveries in ACC biology, reviews the results of early clinical studies with targeted therapies, and provides the rationale for emerging treatment strategies such as immunotherapy.

KW - Adrenocortical carcinoma

KW - IGF-1R

KW - Targeted therapy

KW - VEGFR

KW - β-catenin

UR - http://www.scopus.com/inward/record.url?scp=84979924804&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84979924804&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.8774

DO - 10.18632/oncotarget.8774

M3 - Review article

C2 - 27102148

AN - SCOPUS:84979924804

VL - 7

SP - 46734

EP - 46749

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 29

ER -

Costa R, Carneiro Filho BA, Tavora F, Pai SG, Kaplan JB, Chae YK et al. The challenge of developmental therapeutics for adrenocortical carcinoma. Oncotarget. 2016 Jan 1;7(29):46734-46749. https://doi.org/10.18632/oncotarget.8774